Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase - PubMed (original) (raw)
. 1998 Oct 30;273(44):28766-72.
doi: 10.1074/jbc.273.44.28766.
Affiliations
- PMID: 9786874
- DOI: 10.1074/jbc.273.44.28766
Free article
Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
A G Börsch-Haubold et al. J Biol Chem. 1998.
Free article
Abstract
The kinase inhibitors SB 203580 and PD 98059 have been reported to be specific inhibitors of the 38- and 42/44-kDa mitogen-activated protein kinase (MAPK) pathways, respectively. In this study, the two inhibitors were found to decrease platelet aggregation induced by low concentrations of arachidonic acid, suggesting that they also interfere with the metabolism of arachidonic acid to thromboxane A2. In support of this, SB 203580 and PD 98059 inhibited the conversion of exogenous [3H]arachidonic acid to [3H]thromboxane in intact platelets. Measurement of platelet cyclooxygenase-1 activity following immunoprecipitation revealed that SB 203580 and PD 98059 are direct inhibitors of this enzyme. Both compounds were shown to inhibit purified cyclooxygenase-1 and -2 by a reversible mechanism. In addition, SB 203580 (but not PD 98059) inhibited platelet aggregation induced by prostaglandin H2 and the conversion of prostaglandin H2 to thromboxane A2 in intact platelets. SB 203580 also inhibited this pathway in platelet microsome preparations, suggesting a direct inhibitory effect on thromboxane synthase. These results demonstrate that direct effects of the two kinase inhibitors on active arachidonic acid metabolites have to be excluded before using these compounds for the investigation of MAPKs in signal transduction pathways. This is of particular relevance to studies on the regulation of cytosolic phospholipase A2 as these two MAPKs are capable of phosphorylating cytosolic phospholipase A2, thereby increasing its intrinsic activity.
Similar articles
- Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors.
Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Penglis PS, et al. J Immunol. 2000 Aug 1;165(3):1605-11. doi: 10.4049/jimmunol.165.3.1605. J Immunol. 2000. PMID: 10903770 - Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues.
Boulos C, Jiang H, Balazy M. Boulos C, et al. J Pharmacol Exp Ther. 2000 Apr;293(1):222-9. J Pharmacol Exp Ther. 2000. PMID: 10734173 - Spectrofluorimetric quantification of malondialdehyde for evaluation of cyclooxygenase-1/thromboxane synthase inhibition.
Dannhardt G, Flemmer L, Hartmann RW, Kleber A, Schulze E. Dannhardt G, et al. Arch Pharm (Weinheim). 1998 Nov;331(11):359-64. doi: 10.1002/(sici)1521-4184(199811)331:11<359::aid-ardp359>3.0.co;2-b. Arch Pharm (Weinheim). 1998. PMID: 9881059 - Biosynthesis and pharmacological modulation of thromboxane in humans.
Patrono C. Patrono C. Circulation. 1990 Jan;81(1 Suppl):I12-5; discussion I22-3. Circulation. 1990. PMID: 2136814 Review. - The in vivo assessment of nimesulide cyclooxygenase-2 selectivity.
Shah AA, Murray FE, Fitzgerald DJ. Shah AA, et al. Rheumatology (Oxford). 1999 May;38 Suppl 1:19-23. doi: 10.1093/rheumatology/38.suppl_1.19. Rheumatology (Oxford). 1999. PMID: 10369402 Review.
Cited by
- Effect of miR-412-5p-loaded exosomes in H9c2 cardiomyocytes via the MAPK pathway.
Kim JH, Lee JH. Kim JH, et al. Iran J Basic Med Sci. 2024;27(6):755-760. doi: 10.22038/IJBMS.2024.75590.16365. Iran J Basic Med Sci. 2024. PMID: 38645496 Free PMC article. - Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy.
Perea-Gil I, Seeger T, Bruyneel AAN, Termglinchan V, Monte E, Lim EW, Vadgama N, Furihata T, Gavidia AA, Arthur Ataam J, Bharucha N, Martinez-Amador N, Ameen M, Nair P, Serrano R, Kaur B, Feyen DAM, Diecke S, Snyder MP, Metallo CM, Mercola M, Karakikes I. Perea-Gil I, et al. Eur Heart J. 2022 Sep 21;43(36):3477-3489. doi: 10.1093/eurheartj/ehac305. Eur Heart J. 2022. PMID: 35728000 Free PMC article. - Kinase inhibitors: look beyond the label on the bottle.
Dent P, Poklepovic A, Booth L, Hancock JF. Dent P, et al. Cancer Drug Resist. 2019 Dec 19;2(4):1032-1043. doi: 10.20517/cdr.2019.80. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582272 Free PMC article. Review. - Functions of p38 MAP Kinases in the Central Nervous System.
Asih PR, Prikas E, Stefanoska K, Tan ARP, Ahel HI, Ittner A. Asih PR, et al. Front Mol Neurosci. 2020 Sep 8;13:570586. doi: 10.3389/fnmol.2020.570586. eCollection 2020. Front Mol Neurosci. 2020. PMID: 33013322 Free PMC article. Review. - Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release.
Shin JH, Kwon HW, Rhee MH, Park HJ. Shin JH, et al. J Ginseng Res. 2019 Apr;43(2):236-241. doi: 10.1016/j.jgr.2017.12.007. Epub 2018 Jan 9. J Ginseng Res. 2019. PMID: 30976161 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials